← Home / Cellectar Biosciences, Inc. (CLRB)
Stock Analysis
Cellectar Biosciences, Inc. (CLRB)
CLRB
CLRB · Market data
2.57 +1.58%
Track CLRB in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CLRB price is:
52W Range Position
9%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 19:56 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
2.65
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
10
●
Management / Board
MEDIUM
CLRB board and management update
The proposals presented for stockholder approval at the Annual Meeting are described below: Proposal No.
8-K Filing • SEC EDGAR
JUL
10
●
Shareholder Vote
MEDIUM
CLRB shareholder vote update
The proposals presented for stockholder approval at the Annual Meeting are described below: Proposal No.
8-K Filing • SEC EDGAR
MAY
18
●
Management / Board
MEDIUM
CLRB board and management update
notified the board of directors (the “Board”) of Cellectar Biosciences, Inc.
8-K Filing • SEC EDGAR
What's Driving CLRB?
📈 Technical recovery is improving
Momentum is Neutral. Watch 2.65 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 2.20 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
49.7
◎
How to read this setup
The next meaningful technical decision is likely to occur between support at 2.20 and resistance at 2.65. A move through resistance would be needed to materially improve the chart, while a break of support would keep the pressure side dominant.
Price Chart
CLRB — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$10.9M
Company size
EV
$3.1M
Debt-adjusted value
P/E
-0.5
Not meaningful
P/B
3.3
Balanced
EV/EBIT
-0.1
Not meaningful
P/FCF
-0.6
Not meaningful
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Recovering
⚖
Balance Sheet
Manageable
📈 Net Income
-5.65M
≈ Insufficient
🧮 EPS (Basic)
-1.33
≈ Insufficient
Cellectar Biosciences, Inc.
Related Opportunities